A few years ago, the Organization for Economic Cooperation and Development (OECD) looked at antidepressant use in 25 countries and found something startling.

Significant demographic differences were found when evaluating the use of depression services in people living with HIV and depression.

The recall of the Duloxetine Delayed-Release Capsules, produced by Towa Pharmaceutical Europe, was initiated on October 10 and has been given the second highest risk classification by the FDA.

In the past decade no European country has seen a greater increase in the use of antidepressants; now only the Portuguese and Icelanders are popping more of the pills (see chart 1, showing ...